Primary myelofi brosis

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Myelofibrosis (MF) in the context of a myeloproliferative disorder is a clinicopathologically defined entity characterized by anemia, marked splenomegaly, constitutional symptoms, leukoerythroblastosis (i.e., the presence of immature granulocytes and nucleated red blood cells), dacryocytosis (i.e., presence of teardrop-shaped red blood cells), and a bone marrow that displays dysplastic megakaryocyte hyperplasia, granulocyte proliferation, and reticulin and/or collagen fibrosis (1). Disease presentation could be either de novo (primary MF; PMF) or preceded by either polycythemia vera (post-PV MF) or essential thrombocythemia (post-ET MF). PMF is also known by many other names (Table 2.1), including chronic idiopathic myelofibrosis (CIMF), the term used by the World Health Organization (WHO) system for classification of myeloid neoplasms (2). However, the use of the term PMF was recently endorsed by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) (3).

Original languageEnglish (US)
Title of host publicationRare Hematological Malignancies
PublisherSpringer US
Pages29-49
Number of pages21
ISBN (Print)9780387737430
DOIs
StatePublished - 2008

Fingerprint

Primary Myelofibrosis
Granulocytes
Erythrocytes
Reticulin
Essential Thrombocythemia
Myeloproliferative Disorders
Polycythemia Vera
Megakaryocytes
Splenomegaly
Names
Hyperplasia
Anemia
Fibrosis
Collagen
Bone Marrow
Research
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tefferi, A. (2008). Primary myelofi brosis. In Rare Hematological Malignancies (pp. 29-49). Springer US. https://doi.org/10.1007/978-0-387-73744-7_2

Primary myelofi brosis. / Tefferi, Ayalew.

Rare Hematological Malignancies. Springer US, 2008. p. 29-49.

Research output: Chapter in Book/Report/Conference proceedingChapter

Tefferi, A 2008, Primary myelofi brosis. in Rare Hematological Malignancies. Springer US, pp. 29-49. https://doi.org/10.1007/978-0-387-73744-7_2
Tefferi A. Primary myelofi brosis. In Rare Hematological Malignancies. Springer US. 2008. p. 29-49 https://doi.org/10.1007/978-0-387-73744-7_2
Tefferi, Ayalew. / Primary myelofi brosis. Rare Hematological Malignancies. Springer US, 2008. pp. 29-49
@inbook{a002f498f7224cc6a5d4df26c9a56359,
title = "Primary myelofi brosis",
abstract = "Myelofibrosis (MF) in the context of a myeloproliferative disorder is a clinicopathologically defined entity characterized by anemia, marked splenomegaly, constitutional symptoms, leukoerythroblastosis (i.e., the presence of immature granulocytes and nucleated red blood cells), dacryocytosis (i.e., presence of teardrop-shaped red blood cells), and a bone marrow that displays dysplastic megakaryocyte hyperplasia, granulocyte proliferation, and reticulin and/or collagen fibrosis (1). Disease presentation could be either de novo (primary MF; PMF) or preceded by either polycythemia vera (post-PV MF) or essential thrombocythemia (post-ET MF). PMF is also known by many other names (Table 2.1), including chronic idiopathic myelofibrosis (CIMF), the term used by the World Health Organization (WHO) system for classification of myeloid neoplasms (2). However, the use of the term PMF was recently endorsed by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) (3).",
author = "Ayalew Tefferi",
year = "2008",
doi = "10.1007/978-0-387-73744-7_2",
language = "English (US)",
isbn = "9780387737430",
pages = "29--49",
booktitle = "Rare Hematological Malignancies",
publisher = "Springer US",

}

TY - CHAP

T1 - Primary myelofi brosis

AU - Tefferi, Ayalew

PY - 2008

Y1 - 2008

N2 - Myelofibrosis (MF) in the context of a myeloproliferative disorder is a clinicopathologically defined entity characterized by anemia, marked splenomegaly, constitutional symptoms, leukoerythroblastosis (i.e., the presence of immature granulocytes and nucleated red blood cells), dacryocytosis (i.e., presence of teardrop-shaped red blood cells), and a bone marrow that displays dysplastic megakaryocyte hyperplasia, granulocyte proliferation, and reticulin and/or collagen fibrosis (1). Disease presentation could be either de novo (primary MF; PMF) or preceded by either polycythemia vera (post-PV MF) or essential thrombocythemia (post-ET MF). PMF is also known by many other names (Table 2.1), including chronic idiopathic myelofibrosis (CIMF), the term used by the World Health Organization (WHO) system for classification of myeloid neoplasms (2). However, the use of the term PMF was recently endorsed by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) (3).

AB - Myelofibrosis (MF) in the context of a myeloproliferative disorder is a clinicopathologically defined entity characterized by anemia, marked splenomegaly, constitutional symptoms, leukoerythroblastosis (i.e., the presence of immature granulocytes and nucleated red blood cells), dacryocytosis (i.e., presence of teardrop-shaped red blood cells), and a bone marrow that displays dysplastic megakaryocyte hyperplasia, granulocyte proliferation, and reticulin and/or collagen fibrosis (1). Disease presentation could be either de novo (primary MF; PMF) or preceded by either polycythemia vera (post-PV MF) or essential thrombocythemia (post-ET MF). PMF is also known by many other names (Table 2.1), including chronic idiopathic myelofibrosis (CIMF), the term used by the World Health Organization (WHO) system for classification of myeloid neoplasms (2). However, the use of the term PMF was recently endorsed by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) (3).

UR - http://www.scopus.com/inward/record.url?scp=84888400175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888400175&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-73744-7_2

DO - 10.1007/978-0-387-73744-7_2

M3 - Chapter

AN - SCOPUS:84888400175

SN - 9780387737430

SP - 29

EP - 49

BT - Rare Hematological Malignancies

PB - Springer US

ER -